Clinical Trial Goal
To find out if arlocabtagene autoleucel is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have cancer cells in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CAR stands for chimeric antigen receptors and T stands for T cells, a type of immune cell. This treatment helps your own immune system find and destroy cancer cells.
To make CAR T cells, T cells are collected from you by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow special proteins called CARs. CARs help T cells find the cancer cells. The CAR T cells are grown in a lab until there are millions of them. Then, they’re given back to you to find and destroy the cancer cells.
Before the CAR T-cell infusion, you’ll get chemotherapy (chemo) with standard drugs.
To make CAR T cells, T cells are collected from you by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow special proteins called CARs. CARs help T cells find the cancer cells. The CAR T cells are grown in a lab until there are millions of them. Then, they’re given back to you to find and destroy the cancer cells.
Before the CAR T-cell infusion, you’ll get chemotherapy (chemo) with standard drugs.
Then, the CAR T cells (arlocabtagene autoleucel) are given to you through an IV infusion.
The clinical trial doctors will watch you closely. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 15 years.
The Food and Drug Administration (FDA) has not yet approved arlocabtagene autoleucel.
Watch a video about CAR T-Cell Therapy
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Locations
Sponsors
lead: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
